文献速递颈动脉与弓上血管

颈动脉疾病治疗方式与术后血管活性药物使用及住院时间的关联

Carotid disease treatment modality and its association with postoperative vasoactive medication utilization and hospital length of stay.
PubMed 文献 · J Vasc Surg · 2025-01-28

该回顾性队列研究查询Kaiser Permanente南加州区域数据库2018年1月至2023年12月数据,纳入3012例接受颈动脉内膜剥脱术(CEA)、经股动脉颈动脉支架置入术(TFCAS)或经颈动脉血运重建术(TCAR)的患者,比较术后血管活性药物使用及住院时间。结果显示TCAR患者术后静脉血管活性药物使用比例更高(21.0% vs CEA 6.2% vs TFCAS 7.7%,P < .0001),但术后住院时间更短(2.8天 vs CEA 3.7天 vs TFCAS 5.6天,P < .0001)。

要点

  • TCAR术后静脉血管活性药物使用率21.0%,高于CEA的6.2%和TFCAS的7.7%(P < .0001)。
  • TCAR术后口服米多君处方率9.1%,高于CEA的0.5%和TFCAS的2.0%(P < .001)。
  • TCAR平均术后住院2.8天,短于CEA的3.7天和TFCAS的5.6天(P < .0001)。

核心结论

  • TCAR患者术后需要静脉血管活性药物的可能性高于CEA和TFCAS患者,作者认为这可能继发于球囊血管成形术和支架释放对压力感受器的刺激。
  • 作者认为进一步研究分析为何TFCAS较少出现此现象将有益。
  • 尽管如此,TCAR术后ICU和住院时间更短,结合已报告的获益,作者认为TCAR是颈动脉狭窄手术治疗的有吸引力选择。

研究设计与样本

  • 回顾性队列研究,查询Kaiser Permanente南加州区域数据库2018年1月至2023年12月所有在南加州Permanente医院接受CEA、TFCAS或TCAR的患者,共3012例。
  • 使用χ2检验和Kruskal-Wallis检验分析患者特征并比较各干预方式的药物使用及ICU和干预后住院时间。

主要发现

  • TCAR患者平均术后住院时间2.8天,短于CEA的3.7天和TFCAS的5.6天(P < .0001)。
  • TCAR患者静脉血管活性药物使用率21.0%,高于CEA的6.2%和TFCAS的7.7%(P < .0001)。
  • TCAR患者住院期间任意时点口服米多君处方率9.1%,高于CEA的0.5%和TFCAS的2.0%(P < .001)。

临床怎么用

  • 作者认为,尽管TCAR术后静脉血管活性药物使用更多,但其术后ICU和住院时间更低,结合已报告的获益,TCAR是颈动脉狭窄手术治疗的有吸引力选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Carotid artery disease is a major cause of stroke for which the standard treatment has traditionally been a combination of medical management and intervention, including carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TFCAS). In recent years, transcarotid artery revascularization (TCAR) has been adopted as a promising treatment after US Food and Drug Administration approval in 2015. In terms of stroke reduction, TCAR has been found to have equivalent outcomes with CEA with shorter operative times. A well-described side effect of TCAR is the stimulation of baroreceptors in the carotid bulb, resulting in bradycardia and blood pressure variability that may require vasopressor support. This factor has the potential to lengthen both intensive care unit (ICU) and entire hospital stay. The goal of this retrospective cohort study was to determine whether there is a difference in postoperative vasopressor or vasodilator treatment between traditional CEA, TFCAS, or TCAR and whether it affects ICU and/or overall hospital lengths of stay. METHODS: The Kaiser Permanente Southern California regional database was queried from January 2018 to December 2023 for all patients who underwent CEA, TFCAS, or TCAR at any Southern California Permanente Hospital. The χ2 and Kruskal-Wallis tests were used to analyze patient characteristics and compare medication use and ICU and postintervention length of stay in each intervention modality. RESULTS: The regional database query yielded 3012 patients who had undergone CEA, TFCAS, or TCAR. The average postoperative inpatient length of stay for TCAR patients (2.8 days) was shorter than CEA (3.7 days) and TFCAS (5.6 days) (P < .0001). TCAR patients were more likely to have intravenous vasoactive medication (21.0%) compared with CEA (6.2%) and TFCAS (7.7%) (P < .0001). Also, TCAR patients were more likely to have oral midodrine prescribed at any point in their hospitalization (9.1%) compared with CEA (0.5%) and TFCAS (2.0%) (P < .001). CONCLUSIONS: TCAR patients were more likely to require intavenous vasoactive medication postoperatively compared with CEA and TFCAS patients. This finding is likely secondary to baroreceptor stimulation by balloon angioplasty and stent deployment. Further investigation to analyze why this is not as frequently seen with TFCAS would be beneficial. Despite this, TCAR had lower postoperative ICU and hospital lengths of stay. Combining these findings with already reported benefits makes TCAR an attractive option in the operative treatment of carotid artery stenosis.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Olin NE, Corso JN, Law Y, et al. Carotid disease treatment modality and its association with postoperative vasoactive medication utilization and hospital length of stay. J Vasc Surg. 2025. PMID: 39884562. doi:10.1016/j.jvs.2025.01.193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。